

Commentary

Open Access

A dual role of Cdk2 in DNA damage response

Ande Satyanarayana*² and Philipp Kaldis*¹

Address: ¹Institute of Molecular and Cell Biology (IMCB), Proteos, 61 Biopolis Drive, Singapore 138673, Republic of Singapore and ²Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute-Frederick, Bldg 560/22-69, 1050 Boyles Street, Frederick, Maryland 21702-1201, USA

Email: Ande Satyanarayana* - satya@ncifcrf.gov; Philipp Kaldis* - kaldis@imcb.a-star.edu.sg

* Corresponding authors

Published: 18 May 2009

Received: 20 April 2009

Cell Division 2009, **4**:9 doi:10.1186/1747-1028-4-9

Accepted: 18 May 2009

This article is available from: <http://www.celldiv.com/content/4/1/9>

© 2009 Satyanarayana and Kaldis; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Once it was believed that Cdk2 was the master regulator of S phase entry. Gene knockout mouse studies of cell cycle regulators revealed that Cdk2 is dispensable for S phase initiation and progression whereby Cdk1 can compensate for the loss of Cdk2. Nevertheless, recent evidence indicates that Cdk2 is involved in cell cycle independent functions such as DNA damage repair. Whether these properties are unique to Cdk2 or also being compensated by other Cdks in the absence of Cdk2 is under extensive investigation. Here we review the emerging new role of Cdk2 in DNA damage repair and also discuss how the loss of Cdk2 impacts the G₁/S phase DNA damage checkpoint.

Introduction

Cyclin dependent kinases (Cdks), a family of serine/threonine kinases, faithfully control the mammalian cell cycle by binding to cyclins [1]. Under normal circumstances, D-type cyclins activate Cdk4 and/or Cdk6 and initiate phosphorylation of Retinoblastoma protein (Rb) family early in the G₁ phase [2,3]. This leads to the release of E2F transcription factors and results in activation of transcription of E2F responsive genes required for cell cycle progression [4,5]. In the late G₁ phase, cyclin E activates Cdk2 [2,3] and completes the phosphorylation of Rb leading to passage through the restriction point at the boundary of the G₁/S phase, and to S phase initiation. Later Cdk2 plays an important role in S phase progression by complexing with cyclin A. Finally Cdk1/cyclin B complexes actively participate and complete mitosis [6]. Although it was believed that Cdk2 was essential for S phase entry [7], recent studies found that Cdk2 is dispensable for S phase initiation and progression in vivo and Cdk1 can take over Cdk2's

function in its absence [8-10]. Moreover, it was discovered that Cdk1 alone can drive progression of the mammalian cell cycle by complexing with all the phase specific cyclins in the absence of Cdk2, Cdk4, and Cdk6 [11].

Cdk/cyclin complexes, due to their major role in cell cycle regulation, have become prime targets of inhibition during cellular stress, DNA damage, and telomere dysfunction [12,13]. Two families of Cdk inhibitors regulate the activities and functions of Cdk/cyclin complexes. The INK4 family (p16, p15, p18, p19) specifically bind to Cdk4/Cdk6 and prevent D-type cyclin activity, whereas the Cip/Kip family (p21, p27, p57) inhibits Cdk2/cyclin E, Cdk2/cyclin A as well as Cdk1/cyclin B activity [2,12,14,15]. In response to DNA damage, cell cycle checkpoints (G₁, S, G₂/M) are activated and stop cell cycle progression to allow time for repair thereby preventing transmission of damaged or incompletely replicated chromosomes [12,16]. Cdk2/cyclin E complexes are inhibited

and as a result *Cdk2*^{-/-} cells display delayed resumption of DNA replication due to impaired DNA repair activity. In accordance with this hypothesis, more extensive DNA damage was found in *Cdk2*^{-/-} cells. In addition, a delayed and impaired DNA repair activity was detected in *Cdk2*^{-/-} cells but it appears that *Cdk2*^{-/-} cells do not completely fail to form DNA repair foci (γ H2AX, ATM/ATR substrates) at the sites of damage but rather they exhibited lower numbers of foci for prolonged periods of time [19].

In this context it would be interesting to explore the specific role of Cdk2 in DNA repair. Is Cdk2 part of the DNA repair complex or does Cdk2 play a more indirect role by initiating a signal transduction cascade or activating proteins that are involved in DNA repair? In support of this hypothesis, it was reported that purified Cdk2/cyclin A can phosphorylate S3291 of BRCA2 in vitro [20] and when Cdk2 activity is inhibited by Roscovitine, S3291 phosphorylation of BRCA2 is inhibited. This function is similar to that of Cdk1/cyclin B complexes that are responsible for phosphorylating S3291 of BRCA2 in mitosis, which in turn is necessary for RAD51 binding and DNA repair [21]. Moreover it was shown that cyclin A1 functions in DSB repair and this repair function is dependent on Cdk2 activity [22]. It appears that cyclin A1 is essential for the DNA repair function which in turn depends on the availability of Cdk2. As a result cyclin A1 fails to participate in DNA repair in the absence of Cdk2. This could be due to the lack of a direct interaction between cyclin A1 and Cdk1 as evident from the testis of *Cdk2* knockout mice (no compensation of sterility [9,10]). It has been reported that inhibition of Cdk2 by Roscovitine leads to blunted activation of Chk1 due to reduced phosphorylation [22,23]. Chk1 is one of the downstream targets of the ATM/ATR pathway whose phosphorylation and activation is one of the necessary steps in the DNA damage signal transduction cascade since activated Chk1 in turn activates and promotes several DNA repair proteins to the sites of damage [24]. Two possible mechanisms could explain this phenomenon: 1) Cdk2 might phosphorylate Chk1 along with ATM/ATR there by accelerating the phosphorylation and activation of Chk1. In the absence of Cdk2 the activation process of Chk1 could be delayed resulting in delayed DNA repair; 2) Alternatively Cdk2 phosphorylates Chk1 at sites other than the sites which are phosphorylated by ATM/ATR and phosphorylation of these sites could be essential to complete activation of Chk1.

From the above studies it appears that Cdk2 acts upstream in the DNA damage pathway and is involved in the activation of DNA repair proteins (Figure 1). This is quite different from the downstream role of inhibited Cdk2 in arresting the cell cycle at the checkpoint. An interesting question to answer in this context is how does Cdk2 pro-

mote the activation of DNA repair proteins when it is present in the inhibited state and its kinase activity is inhibited by p21? Maybe, Cdk2 can promote DNA repair activity by direct interactions with other proteins that are involved in double strand break repair. In the inhibited state, Cdk2 is already in complex with cyclin E and/or cyclin A and p21, leaving little interaction space on the surface of the Cdk2 molecule. The observation that *Cdk2* deficient cells display impaired DNA repair capacity indicates that Cdk1 might be unable to perform the DNA repair functions of Cdk2 in the absence of Cdk2 although it is able to trigger the G₁/S DNA damage checkpoint. Another possibility could be that in response to DNA damage in the presence of Cdk2, p21 mainly targets Cdk2 (and only a few Cdk1 molecules) leaving a sub-pool of active Cdk1 that plays a role in DNA repair. This sub-pool of Cdk1 might not be available in the absence of Cdk2 due to higher levels of p21 available to inhibit all of Cdk1. In support to this hypothesis, it was identified that Cdk1 is essential for DNA double strand break repair in yeast [25]. Whether Cdk1 plays a similar role in mammalian cells still needs to be explored.

In contrast to Cdk2's role in the activation of DNA repair pathways it was also shown that Cdk2 phosphorylates FOXO1 in response to chemically induced DNA damage [26]. FOXO transcription factors induce apoptosis by activating a number of genes including Fas, Bim etc. [27]. In this study, a connection between Cdk2 and DNA repair was not detected but they found that FOXO1 phosphorylation and activation by Cdk2 is one of the mechanisms that triggers apoptosis when there is extensive DNA damage in response to chemical treatment that cannot be repaired. This further complicates the role of Cdk2 in DNA damage response. How does Cdk2 distinguish between moderate and extensive DNA damage? Which upstream signaling directs Cdk2 to decide whether to activate Chk1 to repair it or FOXO1 to trigger apoptosis? Although preliminary information suggests a role of Cdk2 in DNA repair in higher eukaryotic cells, it seems that a thorough analysis will be necessary in order to define the specific roles of Cdk2 in DNA repair.

Concluding remarks

From a limited number of studies conducted so far, it emerges that Cdk2 is necessary for proper DNA repair. Nevertheless understanding the specific functions of Cdk2 in DNA repair appears to be challenging due to the complexity of the DNA damage signaling pathway. The most important question to answer is how are Cdk2/cyclin E and/or Cdk2/cyclin A complexes involved in DNA repair when they are present in an inhibited state in response to DNA damage. Although Cdk1 can fully compensate for S phase functions of Cdk2, it fails to compensate for Cdk2's DNA repair functions in mammalian cells. Moreover in

addition to Cdk2's own DNA repair functions, Cdk1's specific role in mammalian DNA damage repair will also need to be resolved.

Acknowledgements

The authors thank members of the Kaldis laboratory for discussions and support. This research was supported by A*STAR of Singapore (P.K.) and the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research (A. S).

References

- Morgan DO: **Cyclin-dependent kinases: engines, clocks, and microprocessors.** *Annu Rev Cell Dev Biol* 1997, **13**:261-291.
- Sherr CJ, Roberts JM: **Cdk inhibitors: positive and negative regulators of G1-phase progression.** *Genes Dev* 1999, **13**:1501-1512.
- Sherr CJ, Roberts JM: **Living with or without cyclins and cyclin-dependent kinases.** *Genes Dev* 2004, **18**:2699-2711.
- Weinberg RA: **The Retinoblastoma protein and cell cycle control.** *Cell* 1995, **81**:323-330.
- Dyson N: **The regulation of E2F by pRB-family proteins.** *Genes & Dev* 1998, **12**:2245-2262.
- Riabowol K, Draetta G, Brizuela L, Vandre D, Beach D: **The cdc2 kinase is a nuclear protein that is essential for mitosis in mammalian cells.** *Cell* 1989, **57**:393-401.
- Heuvel S van den, Harlow E: **Distinct roles for cyclin-dependent kinases in cell cycle control.** *Science* 1993, **262**:2050-2054.
- Aleem E, Kiyokawa H, Kaldis P: **Cdc2-cyclin E complexes regulate the G1/S phase transition.** *Nat Cell Biol* 2005, **7**:831-836.
- Berthet C, Aleem E, Coppola V, Tessarollo L, Kaldis P: **Cdk2 knockout mice are viable.** *Curr Biol* 2003, **13**:1775-1785.
- Ortega S, Prieto I, Odajima J, Martin A, Dubus P, Sotillo R, Barbiero JL, Malumbres M, Barbacid M: **Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice.** *Nat Genet* 2003, **35**:25-31.
- Santamaria D, Barriere C, Cerqueira A, Hunt S, Tardy C, Newton K, Caceres JF, Dubus P, Malumbres M, Barbacid M: **Cdk1 is sufficient to drive the mammalian cell cycle.** *Nature* 2007, **448**:811-815.
- O'Connor PM: **Mammalian G1 and G2 phase checkpoints.** *Cancer Surv* 1997, **29**:151-182.
- Vaziri H, Benchimol S: **From telomere loss to p53 induction and activation of a DNA-damage pathway at senescence: the telomere loss/DNA damage model of cell aging.** *Exp Gerontol* 1996, **31**:295-301.
- Aprelikova O, Xiong Y, Liu ET: **Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase.** *J Biol Chem* 1995, **270**:18195-18197.
- Toyoshima H, Hunter T: **p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21.** *Cell* 1994, **78**:67-74.
- Weinert TA, Hartwell LH: **The RAD9 gene controls the cell cycle response to DNA damage in Saccharomyces cerevisiae.** *Science* 1988, **241**:317-322.
- Giono LE, Manfredi JJ: **The p53 tumor suppressor participates in multiple cell cycle checkpoints.** *J Cell Physiol* 2006, **209**:13-20.
- O'Connell MJ, Cimprich KA: **G2 damage checkpoints: what is the turn-on?** *J Cell Sci* 2005, **118**:1-6.
- Satyanarayana A, Hilton MB, Kaldis P: **p21 Inhibits Cdk1 in the Absence of Cdk2 to Maintain the G1/S Phase DNA Damage Checkpoint.** *Mol Biol Cell* 2008, **19**:65-77.
- Esashi F, Christ N, Gannon J, Liu Y, Hunt T, Jasin M, West SC: **CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair.** *Nature* 2005, **434**:598-604.
- Thorslund T, West SC: **BRCA2: a universal recombinase regulator.** *Oncogene* 2007, **26**:7720-7730.
- Muller-Tidow C, Ji P, Diederichs S, Potratz J, Baumer N, Kohler G, Cauvet T, Choudary C, Meer T Van Der, Chan WY, et al.: **The cyclin A1-Cdk2 complex regulates DNA double-strand break repair.** *Mol Cell Biol* 2004, **24**:8917-8928.
- Deans AJ, Khanna KK, McNees CJ, Mercurio C, Heierhorst J, McArthur GA: **Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers.** *Cancer Res* 2006, **66**:8219-8226.
- Sanchez Y, Bachant J, Wang H, Hu F, Liu D, Tetzlaff M, Elledge SJ: **Control of the DNA damage checkpoint by Chk1 and Rad53 protein kinases through distinct mechanisms.** *Science* 1999, **286**:1166-1171.
- Ira G, Pelliccioli A, Balijja A, Wang X, Fiorani S, Carotenuto W, Liberi G, Bressan D, Wan L, Hollingsworth NM, et al.: **DNA end resection, homologous recombination and DNA damage checkpoint activation require CDK1.** *Nature* 2004, **431**:1011-1017.
- Huang H, Regan KM, Lou Z, Chen J, Tindall DJ: **CDK2-Dependent Phosphorylation of FOXO1 as an Apoptotic Response to DNA Damage.** *Science* 2006, **314**:294-297.
- Fu Z, Tindall DJ: **FOXOs, cancer and regulation of apoptosis.** *Oncogene* 2008, **27**:2312-2319.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

